BACKGROUND: A mobile HIV counseling and testing (HCT) program around Johannesburg piloted the integration of point-of-care (POC) CD4 testing, using the Pima analyzer, to improve linkages to HIV care. We report results from this pilot program for patients testing positive (n = 508) from May to October 2010. METHODS: We analyzed 3 primary outcomes: assignment to testing group (offered POC CD4 or not), successful follow-up (by telephone), and completed the referral visit for HIV care within 8 weeks after HIV testing if successfully followed up. Proportions for each outcome were calculated, and relative risks were estimated using a modified Poisson approach. RESULTS: Three hundred eleven patients were offered the POC CD4 test, and 197 patients were not offered the test. No differences in patient characteristics were observed between the 2 groups. Approximately 62.7% of patients were successfully followed up 8 weeks after HIV testing, with no differences observed between testing groups. Among those followed up, 54.4% reported completing their referral visit. Patients offered the POC CD4 test were more likely to complete the referral visit for further HIV care (relative risk 1.25, 95% confidence interval: 1.00 to 1.57). CONCLUSIONS: In this mobile HCT setting, patients offered POC CD4 testing as part of the HCT services were more likely to visit a referral clinic after testing, suggesting that rapid CD4 testing technology may improve linkage to HIV care. Future research can evaluate options for adjusting HCT services if POC CD4 testing was included permanently and the cost-effectiveness of the POC CD4 testing compared with other approaches for improving linkage of care.
BACKGROUND: A mobile HIV counseling and testing (HCT) program around Johannesburg piloted the integration of point-of-care (POC) CD4 testing, using the Pima analyzer, to improve linkages to HIV care. We report results from this pilot program for patients testing positive (n = 508) from May to October 2010. METHODS: We analyzed 3 primary outcomes: assignment to testing group (offered POC CD4 or not), successful follow-up (by telephone), and completed the referral visit for HIV care within 8 weeks after HIV testing if successfully followed up. Proportions for each outcome were calculated, and relative risks were estimated using a modified Poisson approach. RESULTS: Three hundred eleven patients were offered the POC CD4 test, and 197 patients were not offered the test. No differences in patient characteristics were observed between the 2 groups. Approximately 62.7% of patients were successfully followed up 8 weeks after HIV testing, with no differences observed between testing groups. Among those followed up, 54.4% reported completing their referral visit. Patients offered the POC CD4 test were more likely to complete the referral visit for further HIV care (relative risk 1.25, 95% confidence interval: 1.00 to 1.57). CONCLUSIONS: In this mobile HCT setting, patients offered POC CD4 testing as part of the HCT services were more likely to visit a referral clinic after testing, suggesting that rapid CD4 testing technology may improve linkage to HIV care. Future research can evaluate options for adjusting HCT services if POC CD4 testing was included permanently and the cost-effectiveness of the POC CD4 testing compared with other approaches for improving linkage of care.
Authors: Ilesh V Jani; Nádia E Sitoe; Eunice R Alfai; Patrina L Chongo; Jorge I Quevedo; Beatriz M Rocha; Jonathan D Lehe; Trevor F Peter Journal: Lancet Date: 2011-09-25 Impact factor: 79.321
Authors: Bruce A Larson; Alana Brennan; Lynne McNamara; Lawrence Long; Sydney Rosen; Ian Sanne; Matthew P Fox Journal: Bull World Health Organ Date: 2010-04-16 Impact factor: 9.408
Authors: Gertrude Khumalo-Sakutukwa; Stephen F Morin; Katherine Fritz; Edwin D Charlebois; Heidi van Rooyen; Alfred Chingono; Precious Modiba; Khalifa Mrumbi; Surasing Visrutaratna; Basant Singh; Michael Sweat; David D Celentano; Thomas J Coates Journal: J Acquir Immune Defic Syndr Date: 2008-12-01 Impact factor: 3.731
Authors: Bruce A Larson; Alana Brennan; Lynne McNamara; Lawrence Long; Sydney Rosen; Ian Sanne; Matthew P Fox Journal: Trop Med Int Health Date: 2010-06 Impact factor: 2.622
Authors: Ingrid V Bassett; Susan Regan; Hlengiwe Mbonambi; Jeffrey Blossom; Stacy Bogan; Benjamin Bearnot; Marion Robine; Rochelle P Walensky; Bright Mhlongo; Kenneth A Freedberg; Hilary Thulare; Elena Losina Journal: AIDS Behav Date: 2015-10
Authors: A L Wirtz; C E Zelaya; C Latkin; A Peryshkina; N Galai; V Mogilniy; P Dzhigun; I Kostetskaya; S H Mehta; C Beyrer Journal: Sex Transm Infect Date: 2015-08-21 Impact factor: 3.519
Authors: Wei Chang; Gabriel Chamie; Daniel Mwai; Tamara D Clark; Harsha Thirumurthy; Edwin D Charlebois; Maya Petersen; Jane Kabami; Emmanuel Ssemmondo; Kevin Kadede; Dalsone Kwarisiima; Norton Sang; Elizabeth A Bukusi; Craig R Cohen; Moses Kamya; Diane V Havlir; James G Kahn Journal: J Acquir Immune Defic Syndr Date: 2016-11-01 Impact factor: 3.731
Authors: Clement Zeh; Charles E Rose; Seth Inzaule; Mitesh A Desai; Fredrick Otieno; Felix Humwa; Benta Akoth; Paul Omolo; Robert T Chen; Yenew Kebede; Taraz Samandari Journal: J Immunol Methods Date: 2017-05-18 Impact factor: 2.303
Authors: I V Bassett; S Regan; P Luthuli; H Mbonambi; B Bearnot; A Pendleton; M Robine; D Mukuvisi; H Thulare; R P Walensky; K A Freedberg; E Losina; B Mhlongo Journal: HIV Med Date: 2013-11-19 Impact factor: 3.180
Authors: Zunyou Wu; Zhenzhu Tang; Yurong Mao; Paul Van Veldhuisen; Walter Ling; David Liu; Zhiyong Shen; Roger Detels; Guanghua Lan; Lynda Erinoff; Robert Lindblad; Diane Gu; Houlin Tang; Lian Hu; Qiuying Zhu; Li Lu; Neal Oden; Albert L Hasson; Yan Zhao; Jennifer M McGoogan; Xianmin Ge; Nanci Zhang; Keming Rou; Jinhui Zhu; Hui Wei; Cynthia X Shi; Xia Jin; Jian Li; Julio S G Montaner Journal: Lancet HIV Date: 2017-08-31 Impact factor: 12.767